0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Scoring Systems for Blistering Diseases in Practice Why Bother, and Which One Should You Use?

Dédée F. Murrell, MA, BMBCh, MD, FACD1,2; Masayuki Amagai, MD3; Victoria P. Werth, MD4,5
[+] Author Affiliations
1Department of Dermatology, St George Hospital, Sydney, Australia
2Faculty of Medicine, University of New South Wales, Sydney, Australia
3Department of Dermatology, Keio University, Tokyo, Japan
4Department of Dermatology, Philadelphia Department of Veterans Affairs, Philadelphia, Pennsylvania
5Department of Dermatology, University of Pennsylvania, Philadelphia
JAMA Dermatol. 2014;150(3):245-247. doi:10.1001/jamadermatol.2013.8179.
Text Size: A A A
Published online

Extract

In most countries, pemphigus is one of those rare, potentially life-threatening skin and mucosal diseases that is referred to specialist centers for treatment. Because it is rare, there is a paucity of randomized clinical trials (RCTs) to inform dermatologists of the most effective and safe treatments.1 For rare diseases, meta-analysis, a statistical tool that allows pooling together the results of smaller, similar clinical trials, can be just as valuable as larger clinical trials, but in order to pool the data the studies need to use the same outcome measures for disease assessment.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

694 Views
2 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();